Journal
BLOOD
Volume 134, Issue 14, Pages 1132-1143Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019000402
Keywords
-
Categories
Funding
- Austrian Science Fund FWF [I 4156, I 4154] Funding Source: Medline
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
Ask authors/readers for more resources
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available